Physician profile
Steven Steinberg
NPI 1649284704
$2,326.00
in general payments reported to CMS, 2019-2025
23 companies · $974 in 2025
The $974 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $200 · 2021: $250 · 2022: $41.61 · 2023: $240 · 2024: $227 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431 · Education: $10.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.73 |
| Education | $10.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $377.32 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $336.89 | 2023-2025 | Clareon Panoptix Pro, Clareon, Hydrus Microstent |
| Allergan, INC. | $202.51 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $202.05 | 2019-2021 | |
| Glaukos Corporation | $189.96 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $114.57 | 2023 | Uplizna |
| Johnson & Johnson Surgical Vision, INC. | $110.97 | 2025 | Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $100.01 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.55 | 2019-2021 | |
| Lensar, INC. | $95.49 | 2025 | Lensar Laser System |
| Amgen INC. | $75.91 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $71.44 | 2021 | |
| Abbvie INC. | $61.52 | 2019-2025 | |
| Biotissue Holdings INC. | $60.36 | 2023-2024 | |
| Optos, INC. | $48.50 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $35.95 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.73 | 2019-2021 | |
| Dompe US, INC. | $25.89 | 2022 | |
| Rxsight INC | $20.98 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Sight Sciences, INC. | $20.50 | 2024 | Omni Surgical System |
| Akorn, INC. | $19.30 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.99 | 2020 | |
| Akorn Operating Company LLC | $15.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.